PreveCeutical Medical Inc. announced a non-brokered private placement offering up to 20 million units at $0.03 each, aiming to raise $600,000. Each unit includes one common share and half a warrant, allowing purchase of additional shares at $0.06 within two years. The funds will support loan repayments, legal and audit fees, patents, and further research on rodents and tissues. The offering is subject to regulatory approval and includes a hold period for issued securities. This capital raise supports PreveCeutical's ongoing development of preventive and curative health therapies.
PreveCeutical Medical Inc. announced a private placement to raise $600,000. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 29, 2026 04:11 WIB: 52 of 100 priced US health stocks rose, 47 fell. Amphastar Pharmaceuticals Inc (AMPH) rose 4.09% to USD 27.20 with 99% buy orders and a typical hold time of 16 days. Mesoblast Limited (MESO) fell 4.03% to USD 14.51 with a 13-day hold time. Adaptive Biotechnologies Corp (ADPT) dropped 3.47% to USD 28.41 with 100% buy orders and a 36-day hold time.
Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...
Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...
